Wide Ranks

ABOS

Acumen Pharmaceuticals, Inc.

2.26

Top Statistics
Market Cap 135 M Forward PE -1.48 Revenue Growth 0.00 %
Current Ratio 10.43 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.3720 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 200 M Total Cash Per Share 3.33 Total Debt 29 M
Total Debt To Equity 13.81 Current Ratio 10.43 Book Value Per Share 3.62
All Measures
Short Ratio 621.00 % Message Board Id finmb_8539521 Shares Short Prior Month 1 M
Return On Equity -0.3283 City Charlottesville Uuid 0207450b-6c32-3240-a7c9-bbf75fc2138c
Previous Close 2.20 First Trade Date Epoch Utc 1 B Book Value 3.62
Beta 0.0390 Total Debt 29 M Volume 302139
Price To Book 0.6252 Fifty Two Week Low 2.08 Total Cash Per Share 3.33
Shares Short Previous Month Date 1 B Target Median Price 11.00 Audit Risk 8
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 10.80
Net Income To Common -81672000 Short Percent Of Float 0.0328 Implied Shares Outstanding 60 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 217060
Average Volume10days 217060 Total Cash 200 M Next Fiscal Year End 1 B
Held Percent Insiders 0.1124 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 2.20
Target Low Price 6.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.59
Open 2.20 Free Cashflow -41690752 State VA
Dividend Yield 0.00 % Return On Assets -0.2099 Time Zone Short Name EST
Board Risk 6 Trailing Eps -1.38 Day Low 2.18
Address1 427 Park Street Shares Outstanding 60 M Compensation Risk 9
Price Hint 4 Target High Price 15.00 Website https://acumenpharm.com
52 Week Change -0.0583 Average Volume 198012 Forward Eps -1.53
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 1006.00 %
Is_sp_500 False Regular Market Day High 2.29 Profit Margins 0.00 %
Debt To Equity 13.81 Fifty Two Week High 5.09 Day High 2.29
Shares Short 1 M Regular Market Open 2.20 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0244
Operating Cashflow -67314000 Currency USD Time Zone Full Name America/New_York
Market Cap 135 M Is_nasdaq_100 False Zip 22902
Quote Type EQUITY Industry Biotechnology Long Name Acumen Pharmaceuticals, Inc.
Overall Risk 8 Regular Market Day Low 2.18 Held Percent Institutions 0.7849
Current Price 2.26 Enterprise To Ebitda 0.3720 Financial Currency USD
Current Ratio 10.43 Industry Disp Biotechnology Number Of Analyst Opinions 5
Country United States Float Shares 32 M Two Hundred Day Average 3.04
Governance Epoch Date 1 B Enterprise Value -34574700 Forward PE -1.48
Regular Market Volume 302139 Ebitda -92838000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease.

The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.

The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug.

Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.